386 related articles for article (PubMed ID: 33339226)
1. Distinct Effects of Inflammation on Cytochrome P450 Regulation and Drug Metabolism: Lessons from Experimental Models and a Potential Role for Pharmacogenetics.
de Jong LM; Jiskoot W; Swen JJ; Manson ML
Genes (Basel); 2020 Dec; 11(12):. PubMed ID: 33339226
[TBL] [Abstract][Full Text] [Related]
2. [Clinical significance of cytochrome P450 genetic polymorphism--part I. Enzymatic system of cytochrome P450 and cytochrome P450 1A2].
Duricová J; Grundmann M
Ceska Slov Farm; 2011 Jun; 60(3):110-5. PubMed ID: 21838140
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomics in Critical Care.
Cheek D; Howington L
AACN Adv Crit Care; 2018; 29(1):36-42. PubMed ID: 29496712
[TBL] [Abstract][Full Text] [Related]
4. Addressing phenoconversion: the Achilles' heel of personalized medicine.
Shah RR; Smith RL
Br J Clin Pharmacol; 2015 Feb; 79(2):222-40. PubMed ID: 24913012
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.
Kirchheiner J; Seeringer A
Biochim Biophys Acta; 2007 Mar; 1770(3):489-94. PubMed ID: 17113714
[TBL] [Abstract][Full Text] [Related]
6. Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine.
Shah RR; Smith RL
Drug Metab Dispos; 2015 Mar; 43(3):400-10. PubMed ID: 25519488
[TBL] [Abstract][Full Text] [Related]
7. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology.
Prandota J
Am J Ther; 2005; 12(3):254-61. PubMed ID: 15891270
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future.
Ingelman-Sundberg M
Trends Pharmacol Sci; 2004 Apr; 25(4):193-200. PubMed ID: 15063083
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes.
Rushmore TH; Kong AN
Curr Drug Metab; 2002 Oct; 3(5):481-90. PubMed ID: 12369894
[TBL] [Abstract][Full Text] [Related]
10. Cytochromes P450: decision-making tools for personalized therapeutics.
Murray M; Petrovic N
Curr Opin Mol Ther; 2006 Dec; 8(6):480-6. PubMed ID: 17243482
[TBL] [Abstract][Full Text] [Related]
11. Increasing relevance of pharmacogenetics of drug metabolism in clinical practice.
Pillans PI
Intern Med J; 2001 Nov; 31(8):476-8. PubMed ID: 11720061
[TBL] [Abstract][Full Text] [Related]
12. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
Lynch T; Price A
Am Fam Physician; 2007 Aug; 76(3):391-6. PubMed ID: 17708140
[TBL] [Abstract][Full Text] [Related]
13. Opportunities and obstacles in genotypic prediction of cytochrome P450 phenotypes.
McGraw J; Gerhardt A; Morris TC
Expert Opin Drug Metab Toxicol; 2018 Jul; 14(7):659-661. PubMed ID: 29863909
[No Abstract] [Full Text] [Related]
14. Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment.
Stanke-Labesque F; Gautier-Veyret E; Chhun S; Guilhaumou R;
Pharmacol Ther; 2020 Nov; 215():107627. PubMed ID: 32659304
[TBL] [Abstract][Full Text] [Related]
15. Hepatocytes--the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo.
Gómez-Lechón MJ; Castell JV; Donato MT
Chem Biol Interact; 2007 May; 168(1):30-50. PubMed ID: 17134688
[TBL] [Abstract][Full Text] [Related]
16. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
Zhou SF; Liu JP; Chowbay B
Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of the cytochromes P450.
Daly AK
Curr Top Med Chem; 2004; 4(16):1733-44. PubMed ID: 15579105
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacogenomics: the quest for individualized therapy].
López-López M; Guerrero-Camacho JL; Familiar-López IM; Jung-Cook H; Corona-Vázquez T; Alonso-Vilatela ME
Rev Neurol; 2004 Dec 1-15; 39(11):1063-71. PubMed ID: 15597270
[TBL] [Abstract][Full Text] [Related]
19. CYP450 genotype and pharmacogenetic association studies: a critical appraisal.
Shah RR; Gaedigk A; LLerena A; Eichelbaum M; Stingl J; Smith RL
Pharmacogenomics; 2016 Feb; 17(3):259-75. PubMed ID: 26780308
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. III. Influence of CYP genetic polymorphism on population differentiation of drug metabolism phenotype.
Tomaszewski P; Kubiak-Tomaszewska G; Łukaszkiewicz J; Pachecka J
Acta Pol Pharm; 2008; 65(3):319-29. PubMed ID: 18646551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
